InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

ANAVEX LIFE SCIENCES CORP.

AVXL Clue Score33
United States Fiscal year ends September CIK 0001314052
$1.49 -3.25% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.49 −91.17% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2017Net income−13.5Fiscal year 2018Net income−17.3Fiscal year 2019Net income−26.3Fiscal year 2020Operating income−31.1Net income−26.3Fiscal year 2021Operating income−42.0Net income−37.9EPS, diluted−0.54Fiscal year 2022Operating income−51.0Net income−48.0EPS, diluted−0.62Fiscal year 2023Operating income−55.8Net income−47.5EPS, diluted−0.60Fiscal year 2024Operating income−52.9Net income−43.0EPS, diluted−0.52Fiscal year 2025Operating income−51.4Net income−46.4EPS, diluted−0.54
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income n/a n/a n/a −31.1 −42.0 −51.0 −55.8 −52.9 −51.4
Net income −13.5 −17.3 −26.3 −26.3 −37.9 −48.0 −47.5 −43.0 −46.4
Growth
EPS, diluted n/a n/a n/a n/a −0.54 −0.62 −0.60 −0.52 −0.54
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2017Operating cash flow−9.0Fiscal year 2018Operating cash flow−12.6Fiscal year 2019Operating cash flow−18.5Fiscal year 2020Operating cash flow−21.3Fiscal year 2021Operating cash flow−30.4Fiscal year 2022Operating cash flow−24.2Fiscal year 2023Operating cash flow−27.8Fiscal year 2024Operating cash flow−30.8Fiscal year 2025Operating cash flow−39.0
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −9.0 −12.6 −18.5 −21.3 −30.4 −24.2 −27.8 −30.8 −39.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Cash27.4Shareholders’ equity25.9Fiscal year 2018Cash22.9Shareholders’ equity22.3Fiscal year 2019Cash22.2Shareholders’ equity20.3Fiscal year 2020Cash29.2Shareholders’ equity27.2Fiscal year 2021Cash152.1Shareholders’ equity150.8Fiscal year 2022Cash149.2Shareholders’ equity142.5Fiscal year 2023Cash151.0Shareholders’ equity141.9Fiscal year 2024Cash132.2Shareholders’ equity120.3Fiscal year 2025Cash102.6Shareholders’ equity94.9
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 27.4 22.9 22.2 29.2 152.1 149.2 151.0 132.2 102.6
Shareholders’ equity 25.9 22.3 20.3 27.2 150.8 142.5 141.9 120.3 94.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending September, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Sep 2017 FY2018 30 Sep 2018 FY2019 30 Sep 2019 FY2020 30 Sep 2020 FY2021 30 Sep 2021 FY2022 30 Sep 2022 FY2023 30 Sep 2023 FY2024 30 Sep 2024 FY2025 30 Sep 2025
Revenue and profit
10.7 13.3 22.3 25.2 33.0 37.9 43.7 41.8 37.6
5.0 6.0 6.8 5.9 9.0 13.1 12.0 11.0 13.8
n/a n/a n/a −31.1 −42.0 −51.0 −55.8 −52.9 −51.4
Growth
−13.4 −17.2 −26.2 −26.3 −37.6 −47.6 −47.5 −43.0 −46.4
−13.5 −17.3 −26.3 −26.3 −37.9 −48.0 −47.5 −43.0 −46.4
Growth
Per share
n/a n/a n/a n/a −0.54 −0.62 −0.60 −0.52 −0.54
n/a n/a n/a n/a −0.54 −0.62 −0.60 −0.52 −0.54
Growth
n/a n/a n/a n/a 69.8 76.9 79.8 83.5 85.3
n/a n/a n/a n/a 69.8 76.9 79.8 83.5 85.3
Growth +10.2% +3.7% +4.6% +2.2%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 9 of 9 years on file.